
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC has established a strong foundation for its growth potential through the successful commercialization of its primary product, KIMMTRAK, which has consistently surpassed sales expectations in 12 out of 14 quarters since its FDA and EMA approval in early 2022 for the treatment of unresectable or metastatic uveal melanoma. The company is strategically positioning itself for further expansion by leveraging the ImmTAX platform to develop a diverse pipeline of drug candidates across multiple treatment areas, including oncology, infectious diseases, and autoimmune conditions. Additionally, there is optimism regarding the potential for increased market penetration in the U.S. and further growth opportunities internationally, which could enhance the company's overall revenue trajectory.
Bears say
Immunocore Holdings's stock faces a negative outlook due to disappointing data disclosures from clinical trials, particularly in cutaneous melanoma and ovarian cancer, where the objective response rates (ORR) were significantly below market expectations, with only 11% and 6% respectively. Furthermore, the emergence of competitive products, particularly IDYA's darovasertib and its combination with crizotinib, threatens to diminish the market potential for KIMMTRAK, especially in the HLA-A2+ metastatic uveal melanoma segment. Additionally, risks associated with research and development setbacks, regulatory challenges, and the potential for dilutive financing compound the uncertainties affecting the company's financial stability and stock performance.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares